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Abstract 
Background: Malaria caused by Plasmodium falciparum is still a major health threat in endemic areas especially for 
children below 5 years of age. While it is recognized that antibody immunity plays an important role in controlling 
the disease, knowledge of the mechanisms of sustenance and natural boosting of immunity is very limited. Before, it 
has not been possible to investigate malaria specific B-cells directly in flow cytometry, making it difficult to know how 
much of a B cell response is due to malaria, or how much is due to other immunological stimulators.
Methods: This study developed a technique using quantum dots and schizont extract made from ghosts of infected 
erythrocytes, to be able to investigate P. falciparum specific B-cells, something that has never been done before.
Results: Major differences in P. falciparum specific B-cells were found between samples from immune (22.3 %) and 
non-immune (1.7 %) individuals. Samples from parasite positive individuals had the highest proportions of specific 
B-cells (27.9 %).
Conclusion: The study showed increased levels of P. falciparum-specific B-cells in immune individuals, with the high-
est levels in active malaria infections, using a new technique that opens up new possibilities to study how these cells 
are sustained in vivo after natural infections. It will also be useful in vaccine studies.
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Background
Clinical immunity to Plasmodium falciparum malaria 
is acquired and maintained by repeated exposure to the 
parasite [1]. Classical studies have demonstrated that 
passively transferred IgG from semi-immune adults 
with repeated prior exposure to P. falciparum infection 
can clear or reduce parasitaemia in individuals acutely 
infected with P. falciparum [2]. However, the mechanisms 
by which antibody-secreting cells are induced and main-
tained for long-term disease protection are poorly under-
stood. In order to appreciate how P. falciparum specific 
B-cells are induced and maintained in  vivo, these cells 
need to be separated from other B-cells. The maintenance 
of serum antibody levels after exposure to antigen either 
by infection or immunization has been referred to as 
serological memory [3]. There is long-standing evidence 
that naturally acquired immunity to the erythrocytic 
stages of malaria is strongly dependent on antibodies [4–
8]. Memory B-cells play an important role in memory for 
different pathogens, by boosting the immune response 
in times of secondary exposure. Naturally the kinet-
ics of antibodies is a balance between production and 
decay. Studies have shown that production of antibodies 
against merozoite antigens is not sustained following an 
acute episode of malaria [4, 9]. Antibody production can 
be sustained through restimulation of memory B-cells 
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by persistent antigens [10] or by non-proliferating long 
lived plasma cells [11]. The mechanisms mediating the 
development of short-lived antibody secreting cells and 
long lived plasma cells are not well understood. How-
ever, it appears that short-term serological memory may 
be dependent on antigen stimulation whereas long-term 
serological memory is antigen independent and depends 
on homeostatic activation. Studies have shown that dur-
ing acute malaria infection, there are acute alterations 
in memory B-cell numbers [12]. However, these studies 
used the entire B-cell population without differentiating 
whether they were P. falciparum specific or not.
Controversy still prevails as to why memory in human 
malaria infections is short-lived [13]. Antibody levels to 
some malarial antigens, although not all, have been found 
to rapidly decline after the end of the transmission sea-
son and it has been shown that immunity is short-lived 
in the absence of reinfection [14–19]. This implies that 
B-cell memory to malaria may be defective or subopti-
mal. Weiss et al. [20] provided evidence that an atypical 
memory B-cell population is significantly expanded in P. 
falciparum-exposed Malian adults and children as young 
as 2  years of age. While atypical and classical memory 
B-cells appear closely related developmentally, atypical 
memory B-cells exhibit markedly reduced signaling and 
effector functions, which may contribute to the ineffi-
cient acquisition of humoral immunity to malaria [21].
Some studies in animal models have shown that mem-
ory B-cells do develop and are maintained normally after 
malaria infections [22, 23], whereas others have found 
that malaria infection interferes with the development of 
memory B-cells and long-lived plasma cells [24, 25]. In 
humans, several studies have demonstrated stable anti-
body responses to malaria antigens [26–28]. However, 
short-lived antibody responses have also been observed 
[29, 30], especially in young children [27]. Dorfman et al. 
[30] were frequently unable to detect circulating malaria-
specific B-cells in seropositive children, but it is unclear 
whether this reflects an absence of such cells or a lack of 
sensitivity in the assays used to detect them. Nahrendorf 
et al. [31] showed gradual acquisition of memory B-cells 
and antibodies recognizing pre-erythrocytic and cross-
stage antigens after P. falciparum sporozoite immuniza-
tion. However, the magnitude of these humoral responses 
did not correlate with protection but directly reflected 
parasite exposure in chemoprophylaxis and sporozoites 
immunization and challenge. Asito et  al. [12] observed 
an increase in both the total memory B-cell popula-
tion and the transitional B-cell population, following an 
episode of acute malaria in African children. However, 
this study lacked any analysis of the specificity of B-cell 
responses as well as long-term follow up to ascertain the 
duration of the response. One study showed that even if 
antigen-specific antibodies were not detected in plasma, 
antigen-specific B-cells could still be found circulating 
in the blood, suggesting that these could be maintained 
independently of long-lived plasma cells [32]. Most of 
these studies used Elispot assays for the detection of anti-
gen specific memory B-cells. It has been suggested before 
that flow cytometry is a good method for estimation of 
antigen-specific cells [33] in  situations with complex 
antigens, compared to ELISA-based assays, and malaria 
is certainly a case where there are several setups of anti-
gens, containing a range of merozoite, sporozoite and 
infected erythrocyte antigens where the concentration of 
each specific B-cell is often very low. Even though ELISA-
based assays can be made more sensitive through differ-
ent measures, it is still estimated that they might detect 
only 70 % of the response found when using flow cytom-
etry [33]. An advantage of using direct flow cytometry, 
as in the method described here, is that no stimulation 
of the cells is needed, increasing the chances of includ-
ing all cells in the reading. When this method was used 
in a set of immune and non-immune donors, very clear 
differences were found between the two groups, with the 
highest levels in on-going malaria infection.
Methods
Sample collection and processing
Samples from malaria endemic (n  =  57) and non-
endemic areas (n  =  25) were collected from Kasan-
gati Health Centre, Uganda, and Karolinska University 
Hospital (blood donors), respectively. All samples from 
Kasangati, except seven of the RDT positive samples, 
were collected during the high transmission season. 
Additionally, five samples with an inflammatory condi-
tion other than malaria were collected during the low 
transmission season. 10 Samples each from Ugandan and 
Swedish donors were also collected for protocol stand-
ardization. Written informed consent was obtained from 
all study participants in Uganda and the study protocol 
was approved by the appropriate Ethical review com-
mittee (Uganda: 2011-114, Sweden: 2014-478-32). Blood 
(5–10 mL) was drawn in lithium heparinized tubes (BD, 
Plymouth, UK) and transported to the laboratory for 
processing within 4  h after collection. Peripheral blood 
mononuclear cells (PBMC) were separated by Ficoll-
hypaque (GE HealthCare Bio-Sciences AB, Sweden) 
density gradient centrifugation. The sample blood was 
diluted with equal volumes of Dulbecco’s phosphate buff-
ered saline (DPBS, Life technologies, Stockholm, Swe-
den), carefully layered over the Ficoll, and centrifuged 
for 30 min at 400 g (room temperature) with no brakes. 
After centrifugation, whole blood was separated into four 
layers, with plasma at the top followed by white blood 
cells containing PBMCs, a Ficoll medium layer, and a 
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bottom layer containing erythrocytes and granulocytes. 
After the removal of the plasma, the PBMCs were care-
fully collected, and washed twice with DPBS at 400 g for 
15 min, then 300 g for 15 min to remove Ficoll traces and 
platelets. The cells were then resuspended in 1 mL RPMI 
media (Sigma, St Louis, MO, USA). The Cell count was 
done with the Neuberger counting chamber (5 μL of the 
cell suspension was added to 45 μL of 0.4 % trypan blue, 
Sigma, St Louis, MO, USA). The PBMCs were cryopre-
served in liquid nitrogen at a concentration of 107 cells/
mL in heat-inactivated 90 % fetal bovine serum (Sigma, 
St Louis, MO, USA) and 10 % DMSO (Sigma, St Louis, 
MO, USA) as previously described [34].
Plasmodium falciparum infected red blood cells (iRBCs)
Plasmodium falciparum-infected red blood cells of the 
FCR3S 1.2 line were maintained in vitro at pH 7.4 in seal-
able flasks using human group O+ erythrocytes, at 3 % 
haematocrit, in RPMI-HEPES medium supplemented 
with 50 μg/mL hypoxanthine, 25 mM NaHCO3, 20 μg/
mL gentamicin, 5  % (vol/vol) heat-inactivated pooled 
human sera from donors resident in Sweden, and 0.25 % 
Albumax II (Gibco, Invitrogen, Mount Waverly, Aus-
tralia) maintained in an atmosphere of 1 % O2, 4 % CO2, 
and 95 % N2 at 37 °C, as previously described [35]. Cul-
tures were synchronized two or three times per week by 
resuspending culture pellets in 5 % d-sorbitol (Sigma, St 
Louis, MO, USA) in water to lyse trophozoite- and schiz-
ont-infected erythrocytes.
Ghost Plasmodium falciparum infected red blood cells 
(GiRBCs)
The pellet of 1  ×  108 to 5  ×  108 enriched trophozoite 
stage parasites (~80  % parasitaemia) was treated with 
Streptolysin O (SLO) from Sigma to obtain GiRBCs fol-
lowing the protocol in [36]. SLO treatment of infected 
erythrocytes results in the release of the erythrocyte 
cytosol. Parasites contained within an intact parasito-
phorous vacuole were sedimented by centrifugation at 
10,000×g for 15 s. The pellet (GiRBC) was then homog-
enized using a sonicator (Q500, Fisher Scientific), and the 
protein concentration was measured using a Nanodrop 
(ND2000, Thermoscientific).
Quantum dot (Qdot) conjugation of iRBCs and GiRBCs
Amino Qdot conjugation
35  µL of 2  nmol Qdot 565 amino Qdot (Invitrogen) 
was transferred into a clean dry glass vial. 3.5  µL 
of 1  mM Bis[sulfosuccinimidyl] suberate (BS3) was 
added and incubated for 30  min on a rotator. The 
Qdots were purified from excess cross-linker by buffer 
exchange on a clean centrifugal ultra filtration unit 
(Millipore Corporation), which was pre-equilibrated 
with 3000 µL of PBS (pH 7.4). The collected eluent was 
added to a clean dry vial containing 225  µg of iRBC/
GiRBC and mixed gently, then allowed to react for 2 h 
at room temperature on a rotator. The reaction was 
quenched with 1 M glycine to a final concentration of 
50 mM for 15 min. The conjugate solution was filtered 
through a 0.2 µm poly ether sulfone (PES) syringe fil-
ter over a clean centrifugal ultra filtration unit (Milli-
pore: 100  kDa cutoff ). The filtrate was washed thrice 
with 3 mL of 50 mM borate buffer (pH 8.3) at 3000 g 
for 5  min per wash. The amino Qdot-iRBC/GiRBC 
conjugate solution was diluted 10 times with 10  mM 
Borate buffer (pH 7.4) and stored at 4 °C until further 
processing.
Carboxyl Qdot conjugation
35  µL of 2  nmol Qdot 565 carboxyl Qdots (Invitro-
gen) was transferred into a clean dry glass vial. 199  µL 
of 10  mM borate buffer (pH 7.4) was then added. 
225  µg of iRBCs/GiRBC was added followed by addi-
tion of 7  µL freshly prepared 10  mg/mL N-ethyl-N′-
dimethylaminopropyl-carbodiimide (EDC). The reaction 
mixture was then incubated for 2 h at room temperature 
with gentle stirring. The conjugate solution was filtered, 
washed, and diluted as described above for Amino Qdot 
conjugation.
Immunophenotyping of P. falciparum specific B‑cells
Cryopreserved PBMCs (approximately 1  ×  106 cells) 
were thawed on ice and washed in cold flow buffer 
(PBS/0.5 % BSA/2 mM EDTA). To each sample, 100 µL 
flow buffer was added. To remove non-specific bind-
ing and background fluorescence, 1 µg Fc block (CD16/
CD32mAb, Biolegend) was added to each PBMC sample, 
and incubated on ice for 5  min. 25  µL of GiRBC-Qdot 
conjugate was added, and incubated on ice for 30  min. 
After incubation, the cells were washed and stained for 
CD19 B-cell phenotyping. 3.5 µL CD 19 PE CF594 fluo-
rochrome-conjugated mouse antihuman mAb (BD Hori-
zon) was used to stain 106 cells/100 µL flow buffer. After 
staining for 30  min, cells were washed with flow buffer 
and resuspended in 300 µL flow buffer. Analysis was done 
on a LSRII flow cytometer (Becton–Dickinson Immuno-
cytometry Systems, San Jose, USA). Data was processed 
using FLOWJO software (Tree Star Inc., San Carlos, CA, 
USA).
Malaria diagnostics
All samples from Uganda were subjected to a Combo 
Rapid Diagnostic Test (pLDH/HRP2, Premier Medical 
Corporation Limited, India) as described [37]. The para-
sitaemia for the malaria positive samples was calculated 
using microscopy according to the WHO guide lines [38].
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Results
Comparison between amino Qdots and carboxyl Qdots
To establish the optimal volume of amino/carboxyl Qdot 
conjugate that reacts with the PBMC samples, the vol-
umes of both amino and carboxyl iRBC conjugates were 
varied (from 10, 15, 20, 25, 30, 35, and 40 µL) on the same 
samples from malaria endemic and non-endemic areas. 
25  µL of the conjugate (containing 1  µL Qdot: 6.4  μg 
iRBC/GiRBC) was found to be optimal. Furthermore, 
immune and non immune immunophenotyping based 
on carboxyl Qdot-iRBC conjugate gave a higher P. falci-
parum positive frequency (even though the background 
was also higher), as compared to the amino Qdot-iRBCs 
conjugate, implying that carboxyl Qdots are better sep-
arators for P. falciparum specific B-cells compared to 
amino Qdots (Fig. 1). The mean % of falciparum+ B-cells 
as determined by amino and carboxyl Qdots was 0.27 
and 5.38, respectively, with a p value of <0.0001. The dif-
ference between % of falciparum+ B-cells as determined 
by amino and carboxyl Qdots was statistically significant.
Comparison of carboxyl Qdot‑iRBC and carboxyl 
Qdot‑GiRBC
Despite carboxyl Qdot-iRBC being better separators of 
P. falciparum specific B-cells, they have one short-fall 
of unspecific binding. To reduce on the unspecific bind-
ing of carboxyl Qdot-iRBC conjugate to haemoglobin, 
the GiRBC (which eliminates most of the haemoglobin) 
was prepared and conjugated with carboxyl Qdots as 
described above.
Immunophenotyping experiments to compare carboxyl 
Qdot-iRBC with carboxyl Qdot-GiRBC on four differ-
ent Ugandan blood donors showed that carboxyl Qdot-
GiRBC gave a higher P. falciparum positive percentage as 
depicted in Fig. 2, implying that carboxyl Qdot-GiRBC is 
better than carboxyl Qdot-iRBC.
The mean % of falciparum+ B-cells as determined by 
carboxyl Qdot-RBC and carboxyl Qdot-GiRBC was 1.2 
and 4.6, respectively. The difference between % of falcipa-
rum+ B-cells as determined by carboxyl Qdot-RBC and 
carboxyl Qdot-GiRBC was statistically significant with p 
value of <0.0001.
Comparison of fresh and frozen PBMC
To establish the effect of cryopreservation on PBMC 
using this method, two blood samples from non-immune 
donors were used. The PBMC were isolated from each 
sample using ficoll hypaque as described above. Part of 
the PBMC (fresh) from each sample was immediately 
immunophenotyped (carboxyl Qdot GiRBC and CD 19 
PE CF594 fluorochrome-conjugated mouse antihuman 
mAb) as described above. The remaining portion (frozen) 
was cryopreserved and immunophenotyped the same 
way as the fresh PBMC after 1 week. One sample showed 
1.7 % falciparum+ B-cells when fresh and 1.6 % after hav-
ing been frozen, and the other sample showed 2.2 % both 
as fresh and after freezing. Hence the freezing of PBMC 
has no effect on this technique.
Separation of falciparum+ B‑cells from falciparum− B‑cells 
using carboxyl Qdot‑GiRBC
Immunophenotyping of P. falciparum specific B-cells 
using carboxyl Qdot-GiRBC and CD 19 PE CF594 fluo-
rochrome-conjugated mouse antihuman mAb was con-
ducted on a total of 57 samples from a malaria endemic 
area and 25 samples from a malaria non-endemic area. 
The % of CD19+ cells that were falciparum+ was higher 
in samples from the malaria endemic area (range 13.3–
39.3  %, mean 22.3  %) compared to samples from the 
malaria non-endemic area (range 0.5–2.5 %, mean 1.7 %), 
(Fig. 3).
Reproducibility
To find out how reproducible the method is, four sepa-
rate immunophenotyping experiments were conducted 
(using carboxyl Qdot-GiRBC, and CD 19 PE CF594 
fluorochrome-conjugated mouse antihuman mAb) on 
ten different samples from non-endemic areas using the 
same conditions. The mean and standard deviation per 
sample repeat indicated that the method is very repro-
ducible (Fig. 4).
To further show how reproducible the method is, two 
separate immunophenotyping experiments were con-
ducted on thirteen different samples, of which seven had 
a malaria ongoing infection, five were P. falciparum nega-
tive but with other inflammatory conditions, and one 
sample was from a non-endemic area as a control (Fig. 5). 
The samples from the endemic area were all collected 
during low transmission season. These samples were ran 
twice only because they had fewer cells, compared to 
the above non-immune samples. The mean and stand-
ard deviation for the two experiments on malaria posi-
tive samples was 26.7 (5.8), and 26.8 (5.6), p value = 0.43 
indicating that the difference is not statistically sig-
nificant. The mean and standard deviation for the two 
experiments on inflammatory samples but P. falciparum 
negative was 3.6 (0.4), and 3.5 (0.8), p value = 0.81 indi-
cating that the difference is not statistically significant 
and reproducibility is good, whether high or low values of 
falciparum+ cells are measured.
Comparison of falciparum+ B‑cells and parasitaemia
All the 57 samples from the malaria endemic area 
were screened for malaria using the malaria rapid 
diagnostic test (RDT). Microscopy was done on the 
13 samples that where RDT positive to determine the 
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parasitaemia. The plot of % of falciparum+ B-cells 
and corresponding parasitaemia (Fig.  6) indicated 
that the higher the parasitaemia, the higher the % of 
falciparum+ B-cells. There was no obvious difference 
in results, whether the samples were collected during 
high or low transmission season (Fig.  6). Within the 
immune samples (presented in Fig.  3), the mean and 
standard deviation for the parasite positive (n  =  13) 
and parasite negative (n = 44) samples was 27.9 (6.1), 
and 20.6 (4.9), p value <0.0001.
Fig. 1 Representative flow cytometry experiment from comparison of amino Qdot-iRBCs and carboxyl Qdots-iRBCs conjugate. Immunophenotypy-
ing of both PBMCs samples from malaria endemic (immune) and malaria non-endemic (non immune) areas was done using amino Qdot-iRBC/car-
boxyl Qdot-iRBC, and CD 19 immunophenotyping based on carboxyl Qdot-iRBC gave a better separation of falciparum+ B-cells between immune 
and non-immune samples. a, c Non-immune and immune samples immunophenotyped by amino Qdot-iRBCs; b, d non-immune and immune 
samples immunophenotyped by carboxyl Qdot-iRBCs
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Discussion
Quantum dot nano crystals and bioconjugates are ideal 
for use in flow cytometry, and in this study a novel 
technique for separating P. falciparum specific B-cells 
from other B-cells in humans has been developed. Dif-
ferent Qdots, and different concentration combinations 
were tested and found carboxylated Qdots to be the best 
ones in combination with GiRBC. The removal of hae-
moglobin from the iRBC to form GiRBC was a major 
improvement in removing unspecific binding. It was not 
possible to completely remove unspecific binding, but 
Fig. 2 Example of comparison in flow cytometry of carboxyl Qdot-iRBC and carboxyl Qdot-GiRBC for the same Ugandan blood donor, showing a 















Fig. 3 Immune samples from a malaria endemic area (n = 57), and 
non-immune samples from a non-malaria endemic area (n = 25) 
where immunophenotyped using carboxyl Qdot-GiRBC, and CD 19. 
Immune samples had a significantly higher % of falciparum+ B-cells. 
Circles show immune samples but with a negative Rapid Diagnos-
tic Test collected during high transmission season, triangles show 
immune samples with an ongoing malaria infection collected during 
high transmission season, squares show immune samples with an 
ongoing malaria infection collected during low transmission season 
















Fig. 4 Samples 1–10 from malaria non-endemic area were immu-
nophenotyped four times to test for reproducibility of the assay. Each 
sample was run 4 times, lines indicate mean ± standard deviation
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the differences between immune and non-immune indi-
viduals were so large that an estimation of the percentage 
of P. falciparum specific B-cells in peripheral blood can 
be made. In the individuals with ongoing infection with 
P. falciparum, the levels of B-cells were even higher, indi-
cating that the measure is really a specific response. It is 
also interesting to note that the higher the levels of para-
sites in the blood, the higher the levels of falciparum+ 
B-cells. However, the number of samples with parasites 
in the blood was quite small, and it needs further stud-
ies before any firm conclusions about this can be made. 
All samples were from adults, and since the “immune” 
individuals live in Uganda where malaria occurs all year 
around, they have probably had malaria many times 
before and they can boost a specific response relatively 
quickly. It is interesting to note that the samples collected 
from patients with other inflammatory conditions than 
malaria (5 individuals) in the low transmission season all 
showed lower values compared to many of the samples 
collected earlier in the study during high transmission 
season. Perhaps other B-cells than falciparum+ B-cells 
are boosted, making the relative numbers of falciparum+ 
B-cells lower. For those that had an ongoing infection 
with P. falciparum malaria, the levels of falciparum+ 
B-cells were in the same range whether collected during 
the high-or low transmission season (Fig.  6), indicating 
that an acute infection really boosts falciparum+ B-cells. 
In future studies, investigations on newborns and small 
children can be considered to further try and understand 
the development of P. falciparum specific B-cells early in 
life.
It has for long been a matter of debate, to which 
extent long-term immunity against different antigens 
can be boosted when the individual is exposed to other 
immunostimulatory factors. For malaria, it is quite clear 
that repeated exposure is necessary to reach a high level 
of immunity, but it is not yet understood in detail why it 
takes so long to reach this immunity. Before it has been 
difficult to study malaria specific B-cells, but if the pres-
ently described method is used, it should be easier in 
future to evaluate specific responses, both in naturally 
acquired immunity and in vaccine studies. The study cap-
italized on schizont extract in order to measure all kinds 
of responses, both against merozoites and iRBC surface 
molecules. The advantage of this is that high enough lev-
els of B-cells can be found. If B-cells directed only against 
one specific (recombinant) antigen is looked for, the 
number of B-cells will probably be too low to be found. 
However, a combination of antigens might be a way for-
ward in vaccine studies, where specific responses are 
investigated.
In earlier studies, Elispot assays have been used to try 
and estimate numbers of P. falciparum-specific B-cells. 
In Elispot, the cells have to survive the experimental 
environment with activation of the B-cells and trans-
formation into antibody producing cells, and it is dif-
ficult to know whether all cells actually persist during 
this treatment. Several earlier studies have shown con-
flicting results concerning the correlation between anti-
gen specific IgG levels and memory B-cell frequencies, 
when Elispot has been used [30, 39, 40]. This indicates 
that there might be difficulties in the methods that have 
been used before. It has also been shown that presence 
of malaria specific B-cells measured by Elispot does not 
predict protection from a challenge infection [31]. With 
this new method, no activation of the cells is needed, 

















Fig. 5 Samples 1–13 were used twice each in repeat experiments to 
further test for reproducibility of the assay. Samples 1–7 had on going 
malaria infection, 8–12 had inflammatory conditions other than 
malaria and 13 was from a non-endemic area for comparison. 1–12 
were collected during low transmission season















Fig. 6 Parasitaemia compared to % falciparum+ B-cells, for samples 
from immune individuals who had P. falciparum parasites in the 
blood. Triangles show samples collected during high transmission 
season, squares show samples collected during low transmission 
season
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antigen-specific memory B-cells can directly be detected 
by virtue of their affinity/avidity for cognate antigen 
which makes it advantageous.
Despite flow cytometry having high-throughput 
capabilities, it can be hampered by non specific bind-
ing of some antigens especially repetitive or complex 
multi-protein antigens [41]. Future studies will look 
into sorting of the positive cells and expression of their 
antibodies to determine the extent to which they are P. 
falciparum-specific.
Conclusion
This study has shown that there is a major difference 
in the percentage of P. falciparum-specific B-cells in 
immune compared to non-immune individuals, with the 
highest levels in those that have parasites in the blood. 
Using a new method that opens up new possibilities for 
evaluating P. falciparum-specific B-cells, knowledge 
about how they are sustained in  vivo should be facili-
tated. This method can hopefully be used in both vaccine 
studies that are based on infected RBCs or individual 
antigens that can be conjugated to the carboxyl Qdots, 
and also for studies of development of naturally acquired 
immunity.
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